病例原发 MET 扩增合并脑转移肺癌患者，赛沃替尼治疗实现肺部 PR 及颅内 CR，PFS 达 26 个

导语：赛沃替尼彰显强劲实力，助力原发 MET 扩增更大生存获益。

内容策划：nyh

项目审核：杨静

参考文献：

[1]中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌 MET 临床检测中国专家共识[J]. 中华病理学杂志, 2022, 51(11): 1094-1103.

[2]国家病理质控中心, 中华医学会病理学分会, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌分子病理检测临床实践指南（2024版）[J]. 中华病理学杂志, 2024, 53(10): 981-995.

[3]Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients with MET-amplified NSCLC[J]. J Thorac Oncol, 2021, 16(6):10171029. 

[4]Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10):944957.

[5]Le X, Paz-Ares L, Meerbeeck JV, et al. Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx) [J]. J Clin Oncol, 2022, 40: 16 suppl, 9121-9121.

[6]Sun D, Tao J, Yan W, et al. Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221128414.

[7]Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med. 2021;9(10):1154-1164.

[8]Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023 Jan 9;13(1):98-113.

[9]Ahn MJ, et al. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib. 2023 WCLC EP08.02-140.

[10]J. Yang, et al. Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial. 2024 WCLC. Abs PL04.10.

[11]Glodde N, Bald T, van den Boorn-Konijnenberg D, et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017 Oct 17;47(4):789-802.e9.